Gene expression: Page 2

CareDx reports 13% second-quarter revenue decrease from previous year
By LabPulse.com staff writers
The company expects full-year 2023 revenues to be in the range of $240 million to $260 million.
August 9, 2023
Graph Financial Results Tablet Social
Viome launches at-home oral disease test
By LabPulse.com staff writers
Viome uses the test results to provide consumers with customized food and supplement recommendations that support an individual’s oral and overall health, according to the company.
August 7, 2023
Oral Care Products Resized
Quest Diagnostics launches consumer-initiated genetic test kit
By LabPulse.com staff writers
The test uses next-generation sequencing (NGS) technology to analyze thousands of DNA variants in the genes associated with the conditions within the test’s scope, searching more regions in the individual’s genome than microarray testing.
July 12, 2023
Dna Genome Gene Targeted Social
Castle Biosciences reports study validation for melanoma gene expression test
By Maryam Payne
The study findings support results from a recently published study which showed that patients who received routine imaging guided by high-risk 31-GEP test scores had earlier diagnoses of recurrence, which in turn led to better outcomes for patients.
July 6, 2023
Pathology Slide Melanoma Social
Biocartis, HiloProbe collaborating to commercialize, distribute colorectal cancer gene-expression test
By LabPulse.com staff writers
The test, ColoNode, is CE-marked and will be distributed first as a manual kit by Biocartis to expert laboratories in selected European countries.
May 9, 2023
Dna Genome Gene Targeted Social
Oncocyte to lay off 20% of workforce in cost restructuring
By Leo O'Connor
The CEO said the layoff is part of a plan to bring its cost structure in line with its kitted product strategy and to optimize operational efficiency.
April 13, 2023
Dna Genome Gene Targeted Social
Oncocyte prices $13.86M public offering to support test development, commercialization
By LabPulse.com staff writers
Oncocyte intends to use the net proceeds from the offering primarily to promote the development and commercialization of VitaGraft, DetermaIO, and DetermaCNI precision diagnostic tests.
April 3, 2023
Lung Cancer2 Social
Study supports genetic testing for people with cerebral palsy
By Elissa Wolfson
A meta-analysis of recent cerebral palsy research suggests that genetic testing could be offered as the standard procedure for people with the disorder.
March 7, 2023
Dna Sequencing Data Analysis Social
Immune-response test in study detects COVID-19 with near-perfect accuracy
By Elissa Wolfson
A test that monitors the body’s molecular response to the SARS‑CoV‑2 virus can diagnose even asymptomatic patients with near-perfect accuracy, the researchers said.
March 1, 2023
Coronavirus Covid Blue Social
BlueStar Genomics announces rebranding as ClearNote Health, commercialization of pancreatic cancer test
By LabPulse.com staff writers
The DNA-based blood test is already available in the U.S. through the ClearNote Health physician experience program.
December 22, 2022
Pancreas New Social
Molecular signature in study sheds light on adjuvant radiation therapy after breast-conserving surgery
By LabPulse.com staff writers
Low scores on an investigational gene molecular signature suggest similar rates of local recurrence whether or not patients received adjuvant radiation therapy after breast-conserving surgery.
December 9, 2022
Radiotherapy Breast Cancer Social
Exact Sciences shares validation data for breast cancer radiation signature at SABCS
By LabPulse.com staff writers
The data presented as part of SABCS’s press program were from a meta-analysis of three independent, randomized clinical trials that identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
December 12, 2022
Breast Mammo Social
Previous Page
Page 2 of 4
Next Page